LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Theravance Biopharma Inc

Gesloten

9.43 0.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.2

Max

9.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.8M

-16M

Verkoop

1.9M

19M

EPS

-0.173

Winstmarge

-82.798

Werknemers

97

EBITDA

1.7M

-6.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+62.41% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-13M

440M

Vorige openingsprijs

8.79

Vorige sluitingsprijs

9.43

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Theravance Biopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2025, 20:54 UTC

Acquisities, Fusies, Overnames

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mei 2025, 20:50 UTC

Winsten

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mei 2025, 23:48 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mei 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mei 2025, 23:39 UTC

Marktinformatie

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mei 2025, 23:08 UTC

Marktinformatie

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mei 2025, 22:45 UTC

Acquisities, Fusies, Overnames

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mei 2025, 22:44 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mei 2025, 22:20 UTC

Top Nieuws

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q EPS 10c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Sales $972M >JHX

20 mei 2025, 20:52 UTC

Top Nieuws

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mei 2025, 20:52 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2025, 20:52 UTC

Marktinformatie

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mei 2025, 20:28 UTC

Acquisities, Fusies, Overnames

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mei 2025, 20:23 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Adj EPS BRL2.29 >XP

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Rev BRL4.345B >XP

20 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mei 2025, 20:20 UTC

Top Nieuws

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mei 2025, 20:19 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mei 2025, 20:11 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mei 2025, 20:09 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Peer Vergelijking

Prijswijziging

Theravance Biopharma Inc Prognose

Koersdoel

By TipRanks

62.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.25 USD  62.41%

Hoogste 24 USD

Laagste 10 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Theravance Biopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

9.77 / 10.39Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.